Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics

Kiniksa Pharmaceuticals, Ltd. - (KNSA): $17.89

0.31 (-1.70%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add KNSA to Watchlist
Sign Up

KNSA Price/Volume Stats

Current price $17.89 52-week high $22.09
Prev. close $18.20 52-week low $13.56
Day low $17.76 Volume 80,570
Day high $18.16 Avg. volume 375,221
50-day MA $18.80 Dividend yield N/A
200-day MA $18.10 Market Cap 1.27B

KNSA Stock Price Chart Interactive Chart >


Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio


Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda


KNSA Latest News Stream


Event/Time News Detail
Loading, please wait...

KNSA Latest Social Stream


Loading social stream, please wait...

View Full KNSA Social Stream

Latest KNSA News From Around the Web

Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.

Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), has sold 9,316 shares of the company on December 19, 2023, according to a recent SEC Filing.

Yahoo | December 23, 2023

The 3 Most Undervalued Biotech Stocks to Buy in December

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Gabriel Osorio-Mazzilli on InvestorPlace | December 15, 2023

Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How

Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.

Yahoo | November 24, 2023

Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 70.3% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 20, 2023

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks.

Josh Enomoto on InvestorPlace | November 10, 2023

Read More 'KNSA' Stories Here

KNSA Price Returns

1-mo -7.64%
3-mo -10.42%
6-mo -1.92%
1-year 10.43%
3-year 25.81%
5-year 29.08%
YTD 2.00%
2023 17.09%
2022 27.27%
2021 -33.39%
2020 59.76%
2019 -60.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!